Fixed Income Research - The core viewpoint indicates a divergence in the issuance guidance rates for credit bonds, with medium to high ratings increasing and low ratings decreasing, resulting in an overall change of -6BP to 4BP [2] - In December, the issuance scale of credit bonds decreased month-on-month, with only short-term financing bonds seeing an increase; net financing for credit bonds decreased while company bonds saw an increase [2] - The secondary market saw an increase in transaction volume for credit bonds in December, with yields showing low volatility; the overall credit spread widened, with most varieties at historical low levels [2] - The report suggests that the supply shortage and strong demand for allocation will continue to drive a recovery in credit bonds, with a long-term downward trend in yields expected [2] - The report emphasizes the importance of adjusting strategies in response to market fluctuations and highlights the need to focus on the trends in interest rate bonds while considering the value of individual bonds [2] Financial Engineering Research - The report notes that all major indices rose, with the margin balance continuing to increase, indicating a recovery in valuations and trading opportunities [4] - For the week of December 24-30, all major A-share indices increased, with the CSI 500 showing the largest rise of 2.79% [5] - The margin balance in the two markets reached 25,472.93 billion yuan, an increase of 236.17 billion yuan from the previous week, with the average daily number of investors participating in margin trading rising by 17.70% [5][6] Industry Research - Pharmaceutical and Biological Industry - The report highlights the ongoing trend in the innovative drug industry, with significant developments in regulatory frameworks and a notable increase in the number of approved innovative drugs [12] - In November, the medical care CPI was 101.6, showing a year-on-year increase of 1.6%, while the pharmaceutical manufacturing PPI was 96.1, down 3.9% year-on-year [12] - The report indicates that the innovative drug industry in China is expected to continue its long-term growth trajectory, with a focus on strategic developments in related sectors [12][13] Industry Research - Metals Industry - The report outlines that the steel industry is expected to continue facing weak demand in January 2026, with prices likely to remain low [16] - For copper, the supply is expected to be sufficient, but high prices may suppress downstream demand, leading to a phase of high price fluctuations [16] - The report suggests that the aluminum industry may see improved profitability due to low prices of alumina and strong demand from sectors like new energy vehicles [18] - The report emphasizes the strategic value of rare earth resources and suggests that the industry is poised for future growth, particularly in new energy and robotics sectors [20]

Investment Rating - The report assigns an "Outperform" rating to multiple stocks in the Hong Kong healthcare sector, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene [1][4][37]. Core Insights - The rollout of the "dual formulary" system, which includes the National Reimbursement Drug List (NRDL) and the inaugural Commercial Innovation Drug List, is expected to significantly benefit the innovative drug value chain. The NRDL added 114 drugs with an 88% success rate, up from 76% in 2024, while the commercial list includes 19 innovative drugs [7][40]. - The report highlights three key features of the new drug lists: a focus on innovation, addressing the needs of the elderly and children, and reinforcing the distinction between basic and commercial insurance coverage [7][40]. - The report expresses a long-term positive outlook on the innovative drug value chain, driven by state support for novel drugs and the inclusion of high-innovation therapies in the commercial insurance list [7][40]. Summary by Sections Stock Recommendations - The report lists several top picks for January 2026, including Hansoh Pharma, 3SBio, Kelun-Biotech, Innovent Biologics, Akeso, JD Health, WuXi AppTec, and BeiGene, all rated as "Outperform" [1][4][37]. Market Performance - The December 2025 portfolio of Hong Kong "Golden Picks" saw an average decline of 12.4%, underperforming the Hang Seng Healthcare Index, which fell by 9.5% [5][38]. - Notable performers in December included WuXi AppTec, Akeso, and JD Health, which experienced smaller declines compared to the overall portfolio [5][38]. Industry Trends - The healthcare services sector is noted as undervalued, with companies like Hygeia and Jinxin Fertility showing strong performance due to ongoing market buy-backs [8][41]. - The report suggests monitoring the recovery opportunities in the consumer healthcare sector for 2026, particularly in light of low base effects [8][41]. Recent Developments - A series of business development (BD) deals in December 2025 indicates sustained interest from multinational corporations (MNCs) in the biotech and pharmaceutical sectors, with significant upfront payments and milestone agreements [10][43][44]. - The report emphasizes the attractiveness of the biotech sector following recent valuation resets, suggesting potential for pre-earnings catch-up trades [10][42].

Group 1 - The core viewpoint of the articles highlights the significant interest from brokerages in A-share listed companies, with over 2800 companies receiving brokerage research in 2025, indicating that more than half of the market's listed companies have been under brokerage attention [1][2] - The mechanical equipment, electronics, and pharmaceutical biotechnology sectors are identified as the most favored by brokerages, with over 290 companies in each sector receiving research attention [1][2] - The mechanical equipment sector is particularly noted for investment opportunities in the humanoid robot industry chain, while the electronics sector is advised to focus on new technologies and demands driven by the AI innovation cycle [3][4] Group 2 - Crystal Optoelectronics, a company in the electronics sector, has been the most favored by brokerages, receiving 175 research visits, and is part of a sector that has seen a significant price increase of nearly 42% in 2025 [1][2] - The electronics sector has over 320 companies receiving brokerage research, with notable companies like Huaqin Technology and Luxshare Precision receiving more than 140 research visits each [2] - The pharmaceutical biotechnology sector has 296 companies under brokerage research, with a cumulative increase of only 12.44% in 2025, indicating a relative underperformance compared to other sectors [3][4] Group 3 - Investment opportunities in the humanoid robot sector are expected to grow, with a focus on companies entering the Tesla supply chain and those involved in core supply chain and standardization [3] - The electronics sector is anticipated to benefit from the AI-driven demand for high-performance storage and semiconductor testing equipment, suggesting a favorable outlook for related companies [4] - The pharmaceutical sector is expected to continue focusing on innovative drug companies, supported by favorable policies and increasing international market presence, which will attract more investor attention [4]

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]

Group 1 - The pharmaceutical sector is experiencing a general decline, with notable drops in stock prices for companies such as Genscript Biotech (down 11.02% to HKD 12.92), Sanofi (down 8.27% to HKD 8.32), and others [1] - Haitong International's research report indicates that the recent pullback in the pharmaceutical sector is primarily due to seasonal factors affecting liquidity, particularly the year-end accounting by southbound funds [1] - The report highlights a decreasing proportion of holdings in leading pharmaceutical stocks within the Hong Kong Stock Connect, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 2 - Despite the short-term challenges, the report maintains a positive long-term outlook for the innovative drug industry chain, particularly for companies with strong fundamentals and successful overseas clinical progress [1] - The focus is on companies with strong earnings certainty in internet healthcare, CXO/research services, and leading biotech and pharmaceutical firms that have established external collaborations [1]

Market Overview - The A-share pharmaceutical and biotechnology index fell by 1.17%, underperforming the CSI 300 index by 2.44 percentage points and the ChiNext index by 1.89 percentage points, ranking 17th among 31 sub-industries [4] - The H-share Hang Seng Healthcare Index also declined by 0.71%, lagging behind the Hang Seng Index by 1.45 percentage points [4] R&D Progress - Recent IND applications include Yifang Biotech's D-0502 tablets and Hengrui Medicine's HRS-6257 tablets; clinical applications include BeiGene's BG-C137 injection and Hengrui's HRS-4642 [5] - Shijiazhuang Pharmaceutical's SYS6002 and Zai Lab's Epcoritamab are in Phase III clinical trials; Maiwei Biotech's 9MW3811 is in Phase II; and 3SBio's SSGJ-709 is in Phase I [5] Policy and Market Developments - On December 7, the National Healthcare Security Administration released the new National Basic Medical Insurance Drug Directory and the Commercial Health Insurance Innovative Drug Directory for 2025, with 127 products participating in negotiations, of which 114 were successfully included, achieving a success rate of 88%, the highest in seven years [6] - The first commercial insurance directory included 24 drugs, with 19 successfully negotiated, including CAR-T therapies and treatments for rare diseases such as neuroblastoma and Gaucher disease, as well as Alzheimer's disease [6] - The implementation of the commercial insurance innovative drug directory is expected to open broader market opportunities for innovative drugs in the context of a growing number of "global new" drugs emerging in China [6] Investment Strategy - The investment strategy for the pharmaceutical sector is shifting towards emphasizing the clinical value of drugs, addressing clinical needs of patients, influenced by domestic healthcare policies and global expansion [7] - The focus is on the innovative drug supply chain and innovative medical devices, reflecting a clinical value-based investment approach [7]

Core Viewpoint - The innovative drug sector is experiencing a rebound, with notable stock price increases for several companies following recent policy developments in China's healthcare system [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, priced at HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, trading at HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, now at HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing of innovative drugs for commercial insurance [1] - The fourth batch of traditional Chinese medicine procurement has commenced, and new policies regarding medical devices have been introduced in Beijing [1] - The State Council has outlined plans to advance provincial-level coordination of basic medical insurance [1] Group 3: Investment Opportunities - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, suggesting potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary lull in domestic BD (business development) transactions, there have been multiple collaborations with multinational corporations (MNCs) since Q4, indicating ongoing interest in domestic innovative drug companies [1] - The purchasing behavior of overseas MNCs is seen as a validation of the innovative research capabilities of domestic companies, reflecting China's strong competitive advantages in the global innovative drug industry [1]

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

Core Viewpoint - Fosun Pharma announced that its subsidiary received approval from the National Medical Products Administration for clinical trials of the innovative oral small molecule drug FXS887 for advanced malignant solid tumors, with no approved therapies targeting the same pathway expected until December 3, 2025 [2] Group 1: Company Developments - Fosun Pharma's FXS887 is aimed at treating advanced malignant solid tumors and is notable for being the first of its kind in its target pathway [2] - The approval for clinical trials marks a significant step in the development of innovative therapies within the company [2] Group 2: Market Activity - The pharmaceutical and biotechnology sector saw increased activity, with the STAR Market pharmaceutical ETF (588130) rising by 0.99%, and several holdings such as Yirui Technology, Zai Lab, Rongchang Bio, Dize Pharmaceutical, and Yifang Bio each increasing by over 3% [2] Group 3: Industry Insights - Everbright Securities suggests that investment in the pharmaceutical sector should increasingly focus on the clinical value of drugs, addressing the needs of patients and healthcare providers [2] - The report emphasizes that both domestic healthcare policies and global expansion strategies are placing higher premiums on clinical value, indicating a positive outlook for the innovative drug and medical device industries [2]

Macro and Strategy Research - The report highlights a divergence in the Federal Reserve's stance on interest rate cuts, with a 70% market expectation for a cut in December, although the actual impact may be similar whether it occurs in December or January [3][4] - In the U.S., retail sales showed a slowdown, particularly in the automotive sector, while investment in AI-related fields continues to support economic growth [3] - Domestic industrial profits have declined, with a notable drop in profits for mid and downstream industries, while upstream sectors benefited from stable raw material prices [4] Fixed Income Research - The report indicates a downward trend in the average issuance guidance rates for credit bonds in 2025, with a decrease of 151 basis points to 39 basis points compared to 2024 [5][7] - Credit bond issuance in 2025 decreased compared to the previous year, but net financing increased, indicating a shift in market dynamics [7] - The report emphasizes the importance of liquidity in the bond market, with a focus on the "debt and development" narrative, suggesting that credit risk is perceived to be low [7][8] Industry Research - The report discusses the State Council's initiative to promote provincial-level coordination of basic medical insurance, enhancing the system's security capabilities [13][17] - Recent FDA approvals for innovative treatments, such as BeiGene's Sotigalimab for lymphoma, highlight the ongoing advancements in the biopharmaceutical sector [14][15] - The report notes a decline in the SW pharmaceutical index, with a current P/E ratio of 51.78, indicating a significant premium over the CSI 300 index [16] - The report recommends focusing on investment opportunities in the innovative drug sector, particularly in diagnostics, vaccines, and related pharmaceutical companies [16]